Clinical Trial: The Immunogenicity and Safety of Oral Rotavirus Vaccine (Vero Cell)

U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06967272) titled 'The Immunogenicity and Safety of Oral Rotavirus Vaccine (Vero Cell)' on April 26.

Brief Summary: The Phase II clinical trial of the oral hexavalent reassortant rotavirus attenuated live vaccine (Vero Cells) will be conducted in infants aged 6 to 12 weeks. This study will evaluate the immunogenicity and safety of the investigational vaccine in healthy infants through a randomized, double-blind, active-controlled trial.

Study Start Date: Jan. 20

Study Type: INTERVENTIONAL

Condition: Rotavirus Gastroenteritis

Intervention: BIOLOGICAL: Oral hexavalent reassortant rotavirus attenuated live vaccine

Oral hexavalent reassortant rotavi...